Spark completes FDA application for gene therapy candidate to repair vision loss – Philadelphia Business Journal
pharmaphorum |
Spark completes FDA application for gene therapy candidate to repair vision loss
Philadelphia Business Journal Spark Therapeutics said Thursday it has completed its rolling submission of its biologics license application for its lead gene therapy candidate, voretigene neparvovec, with the Food and Drug Administration. If approved, voretigene neparvovec is in … Submission completed, Spark sets sight on first ever US gene therapy approval Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene … |
